ENCRT-103-hPI for Type 1 Diabetes

This trial tests a treatment called ENCRT-103-hPI for individuals with Type 1 Diabetes. The treatment uses a special soft encasing to protect transplanted islet cells, which help regulate blood sugar, from the immune system. The goal is to determine if this new method is safe and effective. It suits those managing their Type 1 Diabetes who might be waiting for an islet infusion or exploring new treatment options. Participants will keep the implant for about four months and follow a schedule of check-ups. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.

Research has shown that ENCRT-103-hPI is designed for safety and is currently undergoing testing to confirm this. The treatment involves placing a small device under the skin to shield special cells from the immune system. While detailed safety information for this specific treatment remains limited, similar treatments with protective coverings have been well-tolerated in early tests. Early trials like this one typically emphasize safety, with participants closely monitored for any side effects. This careful oversight ensures that any potential issues are managed effectively.

Researchers are excited about ENCRT-103-hPI for Type 1 Diabetes because it offers a novel approach to managing the disease. Unlike traditional treatments that rely on insulin injections or islet cell transplantation, ENCRT-103-hPI uses an implant that potentially provides a more stable and long-term solution for insulin production. The implant is designed to house insulin-producing cells, which could reduce the need for frequent injections and improve blood sugar control. Additionally, in Cohort A, combining this implant with the standard of care might enhance the effectiveness of current treatments, while Cohort B explores the implant's potential as a standalone therapy. This innovation could significantly improve the quality of life for people with Type 1 Diabetes.

Research has shown that ENCRT-103-hPI is designed to protect insulin-producing cells from immune system attacks. Early evidence suggests that this device can prevent scarring around the implant, aiding cell survival. It also facilitates the connection of these cells with blood vessels, crucial for their function. In this trial, participants in Cohort A will receive ENCRT-103-hPI alongside standard of care islet infusion, while those in Cohort B will receive ENCRT-103-hPI only. Previous trials with similar methods demonstrated that patients could become insulin independent, eliminating the need for insulin shots. While these early results are promising, further studies are necessary to confirm these effects in a larger population.¹²³⁴⁵